Latest revenue
$722.5M
as of 2026-03-31
Latest net income
$62.3M
as of 2026-03-31
Net margin
8.6%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Fair value · DCF
DCF: 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Drag the slider to test your own growth thesis — the dominant assumption in any DCF is what comes next, not what the math does with it. Beta defaults to 1.0 when not reported.
Community sentiment
Where do you think AMRX is heading?
Price · 5Y
Market data
Price feed temporarily unavailable for AMRX.
5-year trend
What this company does
Item 1. Business Overview Amneal Pharmaceuticals, Inc. (the “Company”, “we,” “us,” or “our”) is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. Our Affordable Medicines segment includes retail generics, injectables, and biosimilars. In our Specialty segment, we offer a portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through our AvKARE segment, we are a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. We operate principally in the United States (“U.S.”), India, and…
AI summary unavailable — showing raw filing excerpt
Generated from AMRX's filing dated 2026-02-27
Key risks
Item 1A. Risk Factors An investment in our common stock involves a high degree of risk. In deciding whether to invest in our common stock, you should consider carefully the following risk factors, as well as the other information included in this Annual Report on Form 10-K. The materialization of any of these risks could have a material adverse effect on our business, results of operations and financial condition. Operational and Competitive Risks If we cannot successfully develop or commercialize new products, our operating results will suffer. Developing and commercializing a new product is time consuming, costly and subject to numerous obstacles. Our future results of operations depend…
AI summary unavailable — showing raw filing excerpt
Generated from AMRX's filing dated 2026-02-27
Profitability
Gross margin
36.9%
1.0%Operating margin
13.1%
46.3%Net margin
2.4%
157.1%Return on equity
-101.8%
195.1%Return on assets
2.0%
158.7%Leverage
Debt / equity
-52.96×
60.3%Long-term debt / equity
-36.23×
83.1%Debt / assets
101.9%
1.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $722.5M | +3.9% | $62.3M | +410.5% | 8.6% |
Q4 2025 2025-12-31 | $814.3M | +11.5% | $35.1M | +212.9% | 4.3% |
Q3 2025 2025-09-30 | $784.5M | +11.7% | $2.4M | +1618.6% | 0.3% |
Q2 2025 2025-06-30 | $724.5M | +3.2% | $22.4M | +274.0% | 3.1% |
Q1 2025 2025-03-31 | $695.4M | +5.5% | $12.2M | +113.3% | 1.8% |
Q4 2024 2024-12-31 | $730.5M | — | $-31.1M | — | -4.3% |
Q3 2024 2024-09-30 | $702.5M | +13.3% | $-156.0K | -101.6% | -0.0% |
Q2 2024 2024-06-30 | $701.8M | +17.1% | $6.0M | +20.5% | 0.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AMRX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$14.2M
Net activity
−$14.2M
Distinct insiders
8
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AMRX
Institutional value
$1.02B
Total shares held
85.5M
Distinct holders
189
-89 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 24.5M | $304.8M | +10.2M (+71.5%) | Added |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 11.3M | $140.8M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 7.6M | $94.3M | — | New |
| 4 | DIMENSIONAL FUND ADVISORS LP | 5.7M | $70.7M | +81.5K (+1.5%) | Added |
| 5 | Nuveen, LLC | 3.2M | $40.3M | +21.9K (+0.7%) | Added |
| 6 | Invesco Ltd. | 3.2M | $39.6M | +1.4M (+82.1%) | Added |
| 7 | Assenagon Asset Management S.A. | 3.1M | $38.1M | -694.4K (-18.5%) | Trimmed |
| 8 | Allspring Global Investments Holdings, LLC | 2.5M | $32.4M | +1.1M (+72.2%) | Added |
| 9 | Penn Capital Management Company, LLC | 1.2M | $14.9M | +194.1K (+19.4%) | Added |
| 10 | VANGUARD FIDUCIARY TRUST CO | 1.2M | $14.3M | — | New |
| 11 | Phocas Financial Corp. | 1.0M | $12.5M | -1.6M (-60.9%) | Trimmed |
| 12 | PRINCIPAL FINANCIAL GROUP INC | 972.5K | $12.1M | +817.7K (+527.9%) | Added |
| 13 | NEW YORK STATE COMMON RETIREMENT FUND | 954.8K | $11.9M | +113.6K (+13.5%) | Added |
| 14 | JPMORGAN CHASE & CO | 982.3K | $11.7M | +319.7K (+48.2%) | Added |
| 15 | Bank of New York Mellon Corp | 914.1K | $11.4M | +418.2K (+84.3%) | Added |
| 16 | UBS Group AG | 841.0K | $10.5M | -94.5K (-10.1%) | Trimmed |
| 17 | FIRST TRUST ADVISORS LP | 757.2K | $9.4M | +116.9K (+18.3%) | Added |
| 18 | Hillsdale Investment Management Inc. | 743.7K | $9.2M | +29.1K (+4.1%) | Added |
| 19 | BNP PARIBAS FINANCIAL MARKETS | 734.1K | $9.1M | +30.5K (+4.3%) | Added |
| 20 | SEI INVESTMENTS CO | 706.7K | $8.8M | +147.2K (+26.3%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AMRX's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.